# Design Therapeutics DT-216P2 Registrational Update

> Design Therapeutics plans registrational filing for DT-216P2 in Q4 2026 with 12-week results expected Q1 2027.
- Title: Design Therapeutics DT-216P2 Registrational Update | Shortify
- Summary: Design Therapeutics plans registrational filing for DT-216P2 in Q4 2026 with 12-week results expected Q1 2027. Design Therapeutics is holding its lead…
- Keywords: design therapeutics, dt-216p2, friedreich ataxia, gene tac, registrational update, q4 2026, q1 2027, money, business, Design, Therapeutics, Registrational
- Source: Seekingalpha — https://seekingalpha.com/article/4951849-design-therapeutics-hold-dt-216p2-registrational-fa-plans-q4-2026-12-week-results-q1
- Author: Terry Chrisomalis
- Published: 2026-10-04T14:08:05+00:00
- Read time: 1 min
- Topics: design therapeutics, dt-216p2, friedreich ataxia, gene tac, registrational update, q4 2026, q1 2027, money, business
## Investment Rating
Terry Chrisomalis initiates coverage of Design Therapeutics with a hold rating.

> I'm initiating coverage of Design Therapeutics ( DSGN ) with a "Hold" rating
## Lead Candidate Target
Design Therapeutics' lead candidate DT-216P2 targets the root cause of Friedreich Ataxia.

> Design Therapeutics is initiated with a "Hold" rating as its lead candidate, DT-216P2 targets the root cause of Friedreich Ataxia [FA]
## Phase 1/2 Results
The company's 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical improvements.

> The company's 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical improvements
## Upcoming Catalysts
Confirmation of 12-week results for DT-216P2 FA expected in Q1 2027 with registrational update in Q4 2026.

> Upcoming catalysts include a registrational update in q4 2026 for dt-216p2 fa and early-stage readouts for dm1 and fecd programs in 2027
## Cash Position
Design Therapeutics maintains over $200M in cash supporting operations for 12+ months.

> The company maintains over $200M in cash, supporting operations for 12+ months
## Key takeaway

Design Therapeutics is holding its lead candidate DT-216P2 for Friedreich Ataxia with a registrational update planned for Q4 2026 and 12-week results in Q1 2027.